Approved indications
Xtampza ER is FDA-approved for the management of severe and persistent pain that requires daily, around-the-clock, long-term opioid treatment and for which other treatment options (such as non-opioid medicines or immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate; it is not indicated as an as-needed pain medicine.

Off-label uses
Clinicians may use Xtampza ER in a range of severe chronic pain conditions (for example, chronic low back pain, osteoarthritis, or cancer-related pain) when these conditions meet the approved criteria for severity and persistence; there are no major, well-established off-label indications unique to Xtampza ER beyond those general chronic pain uses, and evidence for long-term opioid therapy in many noncancer pain conditions is mixed and emphasizes careful patient selection and monitoring.

Efficacy expectations
Patients usually begin to notice pain relief within the first few doses, with more stable pain control after dose titration over several days; clinical trials in chronic low back pain have shown that, at appropriate doses, Xtampza ER can provide statistically and clinically significant reductions in pain intensity compared with placebo in patients who respond to opioid therapy. At comparable oxycodone doses, its pain-relieving effect is generally similar to other extended-release oxycodone products, while its abuse-deterrent formulation is designed to make certain manipulation methods (such as crushing for snorting or injection) more difficult, though it still carries the same serious risks of addiction, misuse, and overdose as other strong opioids.

Typical dosing and how to take it
For adults who are not opioid tolerant, treatment generally starts with 9 mg by mouth every 12 hours with food, and the dose is then slowly adjusted based on pain control and side effects; single doses above 36 mg or total daily doses above 72 mg are reserved for patients already tolerant to comparable opioids, and the maximum recommended total daily dose is 288 mg. Capsules must always be taken with food, ideally with about the same amount and type of food each time, to keep drug levels consistent.

Administration options
Swallow the capsules whole, or if you cannot swallow capsules, open the capsule and immediately sprinkle the contents on a small amount of soft food or into a cup to be placed directly into the mouth and swallowed without chewing the pellets; the contents can also be given through certain feeding tubes following specific instructions. The capsule contents should never be crushed, chewed, dissolved, or injected, as this can release a potentially fatal dose at once.

Special dosing instructions
People with liver or kidney impairment, older adults, and those taking certain interacting medicines generally require lower starting doses and slower titration, with close monitoring. When switching from other oxycodone formulations, the usual approach is to give the same total daily oxycodone dose divided into two equal Xtampza ER doses 12 hours apart (with food), then adjust as needed; when switching from other opioids, conservative conversion and careful follow-up are essential.

Missed dose and overdose
If a dose is missed, take the next dose at your usual scheduled time and do not take extra capsules to make up for the missed dose. In suspected overdose—such as very slow or stopped breathing, inability to wake up, or severe drowsiness—call emergency services (911) right away and use naloxone if available.

Common side effects
Common side effects include constipation, nausea, vomiting, sleepiness, dizziness, headache, fatigue, abdominal pain, and itching; these often appear when starting treatment or after a dose increase, may lessen over time, and are dose-related, with constipation tending to persist unless treated.

Serious or rare adverse effects
Serious effects that need immediate medical attention include slowed or difficult breathing, extreme drowsiness or inability to wake up, blue or gray lips or fingertips, severe allergic reactions (such as swelling of the face, tongue, or throat or trouble breathing), confusion, seizures, very low blood pressure with fainting, and signs of overdose. Long-term use can lead to physical dependence, addiction, tolerance, hormonal changes, and, if used in pregnancy, life-threatening neonatal opioid withdrawal in the newborn.

Warnings and precautions
Xtampza ER should not be used in people with significant breathing problems, acute or severe asthma without proper monitoring, or known or suspected intestinal obstruction. Use requires extra caution and often lower starting doses in older adults, people with liver or kidney impairment, those with head injury, seizures, mental health or substance use disorders, or low blood pressure. During pregnancy it should be used only if clearly needed due to risk of neonatal withdrawal; breastfeeding is generally not recommended because oxycodone passes into breast milk and may cause serious sedation or breathing problems in the infant.

Safety compared with similar drugs
Overall safety risks (including addiction, overdose, and respiratory depression) are similar to other extended-release opioid pain medicines; the abuse-deterrent formulation can make some forms of manipulation and misuse harder but does not prevent swallowing too many capsules or combining with alcohol or other sedatives, which remains dangerous.

Reporting and safety updates
Side effects can be reported to the FDA MedWatch program (for example, by phone at 1-800-FDA-1088), and updated safety information and Medication Guides are available from the FDA and the manufacturer’s Xtampza ER website.

Drug and substance interactions
Xtampza ER can interact dangerously with other medicines or substances that depress the central nervous system, including other opioids, benzodiazepines, sleep medicines, muscle relaxants, some antipsychotics, alcohol, and certain illicit drugs, increasing the risk of profound sedation, breathing problems, coma, and death. Strong CYP3A4 inhibitors (such as some macrolide antibiotics, azole antifungals, and HIV protease inhibitors) can raise oxycodone levels and cause toxicity, while CYP3A4 inducers (such as rifampin, carbamazepine, and phenytoin) can lower levels and reduce effectiveness or trigger withdrawal. Use with other serotonergic drugs (for example, some antidepressants) may rarely contribute to serotonin syndrome, and combining with anticholinergic drugs may worsen constipation or urinary retention.

Conditions requiring precautions
Use requires particular caution in people with chronic lung disease, sleep apnea, severe obesity, head injury or increased intracranial pressure, seizures, significant liver or kidney impairment, low blood pressure, urinary retention, pancreatitis, gallbladder disease, or a history of substance use disorder, as well as in older adults and those who are frail. Xtampza ER must not be used in people with significant gastrointestinal obstruction.

Monitoring needs
Clinicians typically monitor pain control, breathing, level of alertness, blood pressure, bowel function, and signs of misuse or addiction, especially after starting treatment or changing the dose; in long-term therapy, they may also monitor hormone-related symptoms and perform periodic risk–benefit reassessments. Dose changes may be needed when starting or stopping interacting medications.

Q: Can I open Xtampza ER capsules if I cannot swallow them whole?
A: Yes, you may open the capsule and sprinkle the contents on a small amount of soft food or into a cup to be placed directly into the mouth and swallowed right away, or have them given through certain feeding tubes, but you must not crush or chew the pellets.

Q: Why must Xtampza ER be taken with food?
A: Taking Xtampza ER with food, and with about the same amount of food each time, helps your body absorb a predictable amount of oxycodone and keeps blood levels more stable, which is important for both pain control and safety.

Q: How long does one dose of Xtampza ER last?
A: Each dose is designed to release medicine slowly over about 12 hours, which is why it is usually taken twice a day at the same times.

Q: Is Xtampza ER safer than other opioid pain medicines?
A: Xtampza ER has abuse-deterrent features that can make some kinds of tampering more difficult, but it carries similar serious risks of addiction, misuse, overdose, and life-threatening breathing problems as other strong extended-release opioids when swallowed in high doses or combined with alcohol or sedatives.

Q: What should I do if Xtampza ER is not controlling my pain well enough?
A: Do not change your dose on your own; instead, contact your prescriber to discuss your pain, side effects, and other options, as they may adjust your Xtampza ER dose, change the dosing schedule, add non-opioid treatments, or consider a different therapy.

Storage
Store Xtampza ER at room temperature (about 68°F to 77°F or 20°C to 25°C), in a tightly closed, child-resistant container, away from moisture, heat, and light, and keep it locked or otherwise secured out of sight and reach of children, pets, and others in the household.

Disposal
Because Xtampza ER is a high-risk opioid, expired, unwanted, or unused capsules should be disposed of promptly through a medicine take-back program when possible; if a take-back option is not readily available, the prescribing information allows flushing the unused capsules down the toilet to reduce the risk of accidental ingestion, and you should never share this medication with anyone.